FOR U.S. RESIDENTS ONLY
|
 |

Onychomycosis is prevalent in patients with diabetes
- Patients with diabetes are almost 3 times more likely to get onychomycosis than non-diabetic patients
- Patients with diabetes and onychomycosis have an increased risk of secondary infection*
- Onychomycosis is associated with a 2- to 4-fold increase in diabetic foot infections†
Adapted from Robbins and Doyle, et al.
| † | The efficacy of Penlac® to reduce the incidence of secondary infections has not been determined. |
| * | The risk of removal of the unattached, infected nail by the health care professional, and trimming by the patients, should be carefully considered before prescribing to patients with a history of insulin-dependent diabetes mellitus or diabetic neuropathy. |
|
Penlac®, part of a comprehensive management program, includes regular removal of the unattached, infected nail by a health care professional, especially for patients with diabetes. Clinical data regarding use of systemic antifungals and Penlac® is not available to support concomitant use. Penlac® is well-tolerated: treatment-related side effects were periungual erythema (5%) and nail disorders (2%).
Patients with insulin-dependent diabetes or those with diabetic neuropathy were not included in pivotal clinical trials with Penlac®.